Y Intercept Hong Kong Ltd Grows Stake in SiBone $SIBN

Y Intercept Hong Kong Ltd boosted its stake in SiBone (NASDAQ:SIBN) by 337.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,369 shares of the company’s stock after buying an additional 64,322 shares during the quarter. Y Intercept Hong Kong Ltd owned approximately 0.19% of SiBone worth $1,227,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of SiBone during the first quarter worth approximately $225,000. Goldman Sachs Group Inc. raised its stake in SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after purchasing an additional 83,919 shares during the last quarter. Jane Street Group LLC purchased a new position in SiBone in the 1st quarter valued at $1,818,000. Finally, VELA Investment Management LLC lifted its holdings in SiBone by 2.9% in the 2nd quarter. VELA Investment Management LLC now owns 126,174 shares of the company’s stock valued at $2,375,000 after purchasing an additional 3,503 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at SiBone

In other SiBone news, Director Jeffrey W. Dunn sold 20,000 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $21.28, for a total value of $425,600.00. Following the transaction, the director owned 80,115 shares of the company’s stock, valued at $1,704,847.20. This represents a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael A. Pisetsky sold 3,460 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $19.62, for a total transaction of $67,885.20. Following the completion of the sale, the senior vice president directly owned 228,436 shares in the company, valued at $4,481,914.32. This trade represents a 1.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 207,886 shares of company stock worth $3,996,367 in the last 90 days. Insiders own 4.00% of the company’s stock.

SiBone Stock Up 0.2%

SIBN stock opened at $16.58 on Friday. SiBone has a one year low of $12.49 and a one year high of $21.89. The firm has a market cap of $719.41 million, a PE ratio of -32.51 and a beta of 0.69. The firm’s 50 day moving average price is $18.94 and its 200-day moving average price is $17.01. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. On average, equities research analysts anticipate that SiBone will post -0.78 EPS for the current year.

Analyst Ratings Changes

SIBN has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. TD Cowen raised shares of SiBone to a “strong-buy” rating in a research note on Tuesday, January 27th. Truist Financial raised their target price on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Needham & Company LLC boosted their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Canaccord Genuity Group increased their price target on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, SiBone has an average rating of “Moderate Buy” and an average target price of $24.33.

SiBone Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.